Logo

Compugen and Diagnostic Products to Co-Develop Diagnostics

Sep 08, 2004

NEW YORK, Sept. 8 (GenomeWeb News) - Compugen and Diagnostic Products plan to co-develop diagnostics based on Compugen's biomarkers, the companies said today.

 

Under the agreement, Diagnostic Products, of Los Angeles, plans to develop immunoassay- or nucleic acid-based diagnostics using potential biomarkers provided by Compugen. The companies want to focus on cancer and cardiovascular diseases.

 

Compugen, of Tel Aviv, is entitled to milestone payments as well as royalties on the sales of any diagnostic products. Compugen also has the right to develop any biomarkers for therapeutic purposes.

Breaking News
The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.